Physician profile
Adam James
NPI 1295364586
$1,117.63
in general payments reported to CMS, 2019-2025
13 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.25 · 2024: $731 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $488.51 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $231.83 | 2023-2025 | |
| Lilly USA, LLC | $70.78 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $59.36 | 2024-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $51.31 | 2024 | Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.72 | 2023-2024 | Cycloset, Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $42.88 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $33.33 | 2024 | Inspire |
| Exact Sciences Corporation | $20.80 | 2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.91 | 2024 | Voquezna |
| Dexcom, INC. | $18.68 | 2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $16.90 | 2023 | Nexletol |
| Pfizer INC. | $15.62 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.